Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharvaris ( (PHVS) ) just unveiled an update.
On September 2, 2025, Pharvaris N.V. entered into a registration rights agreement with General Atlantic PH B.V. concerning pre-funded warrants for 500,000 ordinary shares. This agreement, following an underwritten offering closed on July 24, 2025, grants the investor demand registration rights and includes indemnification provisions. This move is likely to impact Pharvaris’s market operations by enhancing its capital structure and providing liquidity options for stakeholders.
The most recent analyst rating on (PHVS) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock’s overall score is affected by these financial and valuation challenges, despite its technical strength.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris N.V. is a company operating in the pharmaceutical industry, focusing on developing oral therapies for hereditary angioedema (HAE). The company is based in the Netherlands and is involved in creating innovative treatments for rare diseases.
Average Trading Volume: 122,699
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.48B
See more insights into PHVS stock on TipRanks’ Stock Analysis page.